449 related articles for article (PubMed ID: 17015050)
1. Determinants of the rate of nicotine metabolism and effects on smoking behavior.
Johnstone E; Benowitz N; Cargill A; Jacob R; Hinks L; Day I; Murphy M; Walton R
Clin Pharmacol Ther; 2006 Oct; 80(4):319-30. PubMed ID: 17015050
[TBL] [Abstract][Full Text] [Related]
2. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking.
Malaiyandi V; Goodz SD; Sellers EM; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1812-9. PubMed ID: 17035386
[TBL] [Abstract][Full Text] [Related]
3. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.
Benowitz NL; Swan GE; Jacob P; Lessov-Schlaggar CN; Tyndale RF
Clin Pharmacol Ther; 2006 Nov; 80(5):457-67. PubMed ID: 17112802
[TBL] [Abstract][Full Text] [Related]
4. Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism.
Ring HZ; Valdes AM; Nishita DM; Prasad S; Jacob P; Tyndale RF; Swan GE; Benowitz NL
Pharmacogenet Genomics; 2007 Dec; 17(12):1007-15. PubMed ID: 18004205
[TBL] [Abstract][Full Text] [Related]
5. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.
Lee AM; Jepson C; Hoffmann E; Epstein L; Hawk LW; Lerman C; Tyndale RF
Biol Psychiatry; 2007 Sep; 62(6):635-41. PubMed ID: 17223085
[TBL] [Abstract][Full Text] [Related]
6. CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy.
Lee AM; Jepson C; Shields PG; Benowitz N; Lerman C; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2007 Jun; 16(6):1312-4. PubMed ID: 17548706
[No Abstract] [Full Text] [Related]
7. The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo.
Sellers EM; Ramamoorthy Y; Zeman MV; Djordjevic MV; Tyndale RF
Nicotine Tob Res; 2003 Dec; 5(6):891-9. PubMed ID: 14668073
[TBL] [Abstract][Full Text] [Related]
8. A meta-analytic review of the CYP2A6 genotype and smoking behavior.
Carter B; Long T; Cinciripini P
Nicotine Tob Res; 2004 Apr; 6(2):221-7. PubMed ID: 15203795
[TBL] [Abstract][Full Text] [Related]
9. CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people.
Binnington MJ; Zhu AZ; Renner CC; Lanier AP; Hatsukami DK; Benowitz NL; Tyndale RF
Pharmacogenet Genomics; 2012 Jun; 22(6):429-40. PubMed ID: 22569203
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism.
Yoshida R; Nakajima M; Watanabe Y; Kwon JT; Yokoi T
Br J Clin Pharmacol; 2002 Nov; 54(5):511-7. PubMed ID: 12445030
[TBL] [Abstract][Full Text] [Related]
11. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence.
Malaiyandi V; Sellers EM; Tyndale RF
Clin Pharmacol Ther; 2005 Mar; 77(3):145-58. PubMed ID: 15735609
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking.
Sellers EM; Kaplan HL; Tyndale RF
Clin Pharmacol Ther; 2000 Jul; 68(1):35-43. PubMed ID: 10945314
[TBL] [Abstract][Full Text] [Related]
13. Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort.
Gambier N; Batt AM; Marie B; Pfister M; Siest G; Visvikis-Siest S
Pharmacogenomics J; 2005; 5(4):271-5. PubMed ID: 15940289
[TBL] [Abstract][Full Text] [Related]
14. CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation.
Kubota T; Nakajima-Taniguchi C; Fukuda T; Funamoto M; Maeda M; Tange E; Ueki R; Kawashima K; Hara H; Fujio Y; Azuma J
Pharmacogenomics J; 2006; 6(2):115-9. PubMed ID: 16402086
[TBL] [Abstract][Full Text] [Related]
15. Metabolism and disposition kinetics of nicotine.
Hukkanen J; Jacob P; Benowitz NL
Pharmacol Rev; 2005 Mar; 57(1):79-115. PubMed ID: 15734728
[TBL] [Abstract][Full Text] [Related]
16. Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans.
Nakajima M; Yamagishi S; Yamamoto H; Yamamoto T; Kuroiwa Y; Yokoi T
Clin Pharmacol Ther; 2000 Jan; 67(1):57-69. PubMed ID: 10668854
[TBL] [Abstract][Full Text] [Related]
17. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.
Dempsey D; Tutka P; Jacob P; Allen F; Schoedel K; Tyndale RF; Benowitz NL
Clin Pharmacol Ther; 2004 Jul; 76(1):64-72. PubMed ID: 15229465
[TBL] [Abstract][Full Text] [Related]
18. Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data.
Cox LS; Faseru B; Mayo MS; Krebill R; Snow TS; Bronars CA; Nollen NL; Choi WS; Okuyemi KS; Salzman GA; Benowitz NL; Tyndale RF; Ahluwalia JS
Trials; 2011 Jan; 12():22. PubMed ID: 21266057
[TBL] [Abstract][Full Text] [Related]
19. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.
Schoedel KA; Hoffmann EB; Rao Y; Sellers EM; Tyndale RF
Pharmacogenetics; 2004 Sep; 14(9):615-26. PubMed ID: 15475735
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.
Nakajima M; Fukami T; Yamanaka H; Higashi E; Sakai H; Yoshida R; Kwon JT; McLeod HL; Yokoi T
Clin Pharmacol Ther; 2006 Sep; 80(3):282-97. PubMed ID: 16952495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
